Skip to main content

Table 1 Baseline characteristics of the study population

From: Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation

Baseline Characteristics Whole Cohort
Age (years, mean ± SEM) 44.4 ± 1.2
Gender (n [%] female) 88/103 [85%]
Number of previously tried preventatives (median [95% CI]) 7 [7, 8]
Non-responder to botulinum toxin A (n [%]) 97/103 [94%]
Current medication overuse 50/103 [49%]
Headache days (median [95% CI]) 28 [28 – 28]
Severe headache days (median [95% CI]) 15 [12-18]
Current daily headache pattern (n [%]) 62/103 [60%]
  1. SEM Standard error of the mean. CI Confidence interval